The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.
暂无分享,去创建一个
G Flandrin | J Diebold | C. Bloomfield | J. Diebold | N. Harris | T. Lister | H. Muller-Hermelink | E. Jaffe | G. Flandrin | J. Vardiman | E S Jaffe | H. Muller-Hermelink | C D Bloomfield | N L Harris | H K Muller-Hermelink | J Vardiman | T A Lister
[1] V. Diehl,et al. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Mclaughlin,et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Coiffier,et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. , 1993, The New England journal of medicine.
[4] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[5] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[6] H Tesch,et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Hancock,et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[10] J. Gribben,et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Kantarjian,et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Hainsworth,et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. , 2000, Blood.
[13] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[15] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[17] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[18] A. Norton,et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[20] L. Gordon,et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] T. Lister,et al. Follicular lymphoma: prognostic factors for response and survival. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Armitage,et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] V. Diehl,et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] B. Coiffier,et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] W. Chan,et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Weisenburger,et al. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[28] J. Gribben,et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. , 1999, Blood.
[29] R B Mann,et al. Criteria for the cytologic subclassification of follicular lymphomas: A Proposed alternative method , 2007, Hematological oncology.
[30] R. Fisher,et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Grever,et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. , 2000, Blood.